Our mission is to empower clinicians with Biomarkers allowing them to identify Neurological Disorders (Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis) years before visible symptoms.
neuroClues has raised €15M across 2 funding rounds from 6 investors, most recently a Series A round in Apr 2026. Based in Louvain-la-Neuve, Belgium; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-04-07 | Series A | €10.0M | EIC Fund,Existing investors,Olivier Legrain,TeamPact Ventures,White Fund | View deal → |
| 2024-04-30 | Seed | €5.0M | the European Commission’s EIC Accelerator program,White Fund | View deal → |
